Annexon, Inc. (ANNX)
$
2.19
-0.16 (-7.31%)
Key metrics
Financial statements
Free cash flow per share
-0.9445
Market cap
240.3 Million
Price to sales ratio
0
Debt to equity
0.1161
Current ratio
7.9936
Income quality
0.8352
Average inventory
0
ROE
-0.5445
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Annexon, Inc., a clinical-stage biopharmaceutical company headquartered in Brisbane, California, specializes in uncovering and developing therapeutic solutions for autoimmune, neurodegenerative, and ophthalmic disorders. The total costs and expenses for the company are $0.00 reflecting its overall spending. With a strategic focus on niche markets, the company achieved a revenue of $0.00 indicating its concentrated approach in specific therapeutic areas. Moreover, the operating income ratio stands at 0.00 illustrating the company's operational profitability margin, while the gross profit ratio is 0.00 which highlights the efficiency of its production and sales operations. The gross profit amounts to $0.00 showcasing the company's robust profitability from its core operations. Among its various product candidates, ANX005, a monoclonal antibody, is undergoing Phase II/III clinical trials targeting Guillain-Barré syndrome, as well as a Phase II trial for warm autoimmune hemolytic anemia, and additional studies for Huntington's disease and amyotrophic lateral sclerosis. The company is also advancing ANX009, currently in a Phase Ib trial for lupus nephritis, and ANX007 in Phase II trials aimed at geographic atrophy. Additional investigational products include ANX105, targeting neurodegenerative conditions, and ANX1502, an oral small molecule for specific autoimmune disorders. As a small-cap player with a market capitalization of $240,273,660.00 Annexon is a significant entity in the Biotechnology industry, contributing meaningfully to the overall market landscape. The stock is affordable at $2.61 making it suitable for budget-conscious investors. Furthermore, the stock has a high average trading volume of 1,502,443.00 indicating strong liquidity, which is essential for investors seeking actively traded shares. As a member of the Healthcare sector, Annexon is driving innovation and growth in its field, demonstrating its commitment to enhancing the treatment landscape for patients with challenging medical conditions.
Is Annexon, Inc. (ANNX) a good investment?
Investing in Annexon, Inc. (ANNX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Annexon, Inc. (ANNX)'s stock forecast?
Analysts predict Annexon, Inc. stock to fluctuate between $1.29 (low) and $7.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Annexon, Inc.'s market capitalization?
As of 2025-08-20, Annexon, Inc.'s market cap is $240,273,660, based on 109,714,000 outstanding shares.
How does Annexon, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Annexon, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Annexon, Inc. (ANNX) stock?
To buy Annexon, Inc. (ANNX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANNX. Place an order (Market, Limit, etc.).
What is the best time to invest in Annexon, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Annexon, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.01 | Growth: -42.94%.
Where can I find Annexon, Inc.'s investor relations reports?
Visit https://www.annexonbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Annexon, Inc.?
You can explore historical data from here
What is the all-time high and low for Annexon, Inc. stock?
All-time high: $23.61 (2021-09-17) | All-time low: $1.29 (2025-04-10).
What are the key trends affecting Annexon, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
zacks.com
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
seekingalpha.com
Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, given the lack of FDA-approved therapies and limited competition. The company faces near-term risks: delayed regulatory filings, high cash burn, and a likely need for additional funding within a year.
globenewswire.com
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 14, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida.
See all news
